MichelleAPetriMD

Rheumatology • Baltimore, MD

Professor of Medicine, Johns Hopkins University School of Medicine; Director, Hopkins Lupus Center

Join to view full profile

Dr. Petri is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Petri's full profile

Already have an account?

Office
601 North Caroline Street
Baltimore, MD 21287
Phone+1 410-955-9114

Fax+1 410-614-0498

Education & Training

University of California (San Francisco)Residency, Internal Medicine, 1983 - 1984
Massachusetts General HospitalResidency, Internal Medicine, 1980 - 1983
Harvard Medical SchoolClass of 1980

Certifications & Licensure

CA State Medical License 1983 - Present
FL State Medical License 2020 - Present
MD State Medical License 1986 - 2025
NC State Medical License 2020 - 2022
American Board of Allergy and Immunology Allergy & Immunology
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Top Doctors:Baltimore Area Castle Connolly, 2012
Top Doctors:Washington-Baltimore Castle Connolly, 2012
Super Doctor SuperDoctors.com
Fellow (FACR) American College of Rheumatology
Join now to see all

Clinical Trials

Safety of Estrogens in Lupus: Hormone Replacement Therapy Start of enrollment: 1996 Apr 01
Terminated
Phase 3
Safety of Estrogens in Lupus: Birth Control Pills Start of enrollment: 1997 Jun 01
Completed
Phase 3
High-Dose Intravenous (IV) Cyclophosphamide Versus Monthly IV Cyclophosphamide Start of enrollment: 2000 Jan 01
Completed
Phase 3
Lupus Atherosclerosis Prevention Study Start of enrollment: 2002 Apr 01
Completed
Phase 4
Memantine in Systemic Lupus Erythematosus Start of enrollment: 2006 Mar 01
Completed
Not Applicable
Efficacy of Fish Oil in Lupus Patients Start of enrollment: 2009 Feb 01
Completed
Phase 4
Doxycycline Outcomes in Lupus Erythematosus Start of enrollment: 2010 Sep 01
Withdrawn
Phase 4
Levothyroxine in Pregnant SLE Patients Start of enrollment: 2011 Jan 01
Withdrawn
Phase 4
A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus Start of enrollment: 2011 Nov 01
Terminated
Phase 2
International Prospective Study on Adherence to Treatment in Patients With Active Systemic Lupus Erythematosus Start of enrollment: 2013 Jan 01
Completed
Join now to see all

Publications & Presentations

PubMed

Patients achieving low lupus disease activity state, systemic lupus erythematosus disease control or remission showed lower rates of organ damage during longitudinal f...
Jacob Hunnicutt, Mary Elizabeth Georgiou, Anna Richards, Holly Quasny, Laurence Magder
Lupus Science & Medicine. 2024-12-11
SOX-5 Transcription Factor: a Novel Psoriatic Autoantigen Preferentially Found in Women.
Ana-Maria Orbai, David Fiorentino, Jamie Perin, Erika Darrah, Qingyuan Yang
ACR Open Rheumatology. 2024-12-01
Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-D Report: Multicriteria Decision Analysis.
Medha Barbhaiya, Stephane Zuily, Mary-Carmen Amigo, Danieli Andrade, Tadej Avcin
Arthritis Care & Research. 2024-12-01

Journal Articles

Psychosis in Systemic Lupus Erythematosus
Anca Askanase, Kenneth C Kalunian, M A Dooley, Meggan Mackay, Ellen M Ginzler, Daniel J Wallace, Susan Manzi, Cynthia Aranow, Joan T Merrill, Michelle Petri, Diane L K..., Arthritis & Rheumatology
Factors Associated with First Thrombosis in Patients Presenting with Obstetric Antiphospholipid Syndrome in APS Alliance for Clinical Trials & International Networking...
Doruk Erkan, Michelle Petri, H Michael Belmont, Jason S Knight, BJOG: An International Journal of Obstetrics & Gynaecology
Reply to: Is Low Disease Activity Good Enough as a Target in Systemic
Michelle Petri, MD, Arthritis & Rheumatology
A Prospective International Study on Adherence to Treatment in 305 Patients with Flaring SLE: Assessment by Drug Levels and Self‐Administered Questionnaires
Peter Izmirly, Michelle Petri, Meenakshi Jolly, Jill Buyon, Clinical Pharmacology & Therapeutics
Hydroxychloroquine Prescription Trends and Predictors for Excess Dosing Per Recent Ophthalmology Guidelines
S Sam Lim, Anca Askanase, Michelle Petri, Karen H Costenbader, Ronald B Melles, Cynthia Aranow, April M Jorge, BioMed Central
Join now to see all

Lectures

Longitudinal Stratification of Gene Expression Reveals Three SLE Groups of Disease Activity Progression
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Authored Content

A Urinary Biomarker Panel to Predict the Probability of Histologically Active Lupus NephritisNovember 2024
Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 TrialOctober 2024

Press Mentions

Physician-Scientists to Review Ongoing Efforts to Reduce Steroid Use in Treating Rheumatic DiseasesNovember 16th, 2024
Making Sense of the Connection Between Vaccines and Lupus FlaresAugust 8th, 2024
CAR T-cell Therapy May Be a ‘Miracle,’ but It Is Too Soon to Say ‘Cure’July 22nd, 2024
Join now to see all

Grant Support

Hopkins Lupus CohortNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1997–2012
Revision Of ACR Classification Criteria For Systemic Lupus ErythematosusNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2007
Cognitive Function In Systemic Lupus ErythematosusNational Center For Research Resources2007
Brain Connections: Add-On Study Of Serial Brain Mris Every SIX MonthsNational Center For Research Resources2007
Systemic Lupus Erythematosus (SLE)National Center For Research Resources2005–2007
Prospective Lupus Cohort Study Of Disease Activity And Predictors Of MorbidityNational Center For Research Resources2004–2007
Lupus Atherosclerosis Prevention Study (LAPS)National Center For Research Resources2004–2007
Lupus Atherosclerosis Prevention Study (Laps)Par }National Center For Research Resources2006
Brain Conections: Add-On Study Of Serial Brain Mris Every SIX MonthsNational Center For Research Resources2006
Lupus Atherosclerosis Prevention Study (LAPS) SupplementNational Center For Research Resources2004–2006
Lupus CohortNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2002–2006
Brain ConnectionsNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2002–2006
Revision Of ACR Classification Criteria For SLENational Institute Of Arthritis And Musculoskeletal And Skin Diseases2005
Program Project In The Genetics Of SLENational Center For Research Resources2004–2005
Revision Of ACR Classification Criteria For SLENational Institute Of Arthritis And Musculoskeletal And Skin Diseases2004
Phase II Trial Of Idec 131 In Patients With Active SLENational Center For Research Resources2000–2002
Oral Contraceptive And Hormone Replacement In SLENational Center For Research Resources2000–2002
Genetic Risk Profile In Longitudinal SLE CohortsNational Center For Research Resources1999–2002
Specialized Center Of Research--Systemic Lupus ErythrmatosusNational Center For Research Resources1998–2002
Prospective Lupus Cohort Study Of Disease Activity/Predictors/Morbidity/HealthNational Center For Research Resources1998–2002
Oral Contraceptive And Hormone Replacement In Systemic Lupus ErythematosusNational Center For Research Resources1998–2002
Multicenter Trial Of Repeated Dose Of LJP 394 In Patients With SLENational Center For Research Resources1998–2002
Gl701 In Females With Active Systemic Lupus ErythematosusNational Center For Research Resources1998–2002
Detection Of Atherosclerosis In Systemic Lupus ErythematosusNational Center For Research Resources1998–2002
Autoantibody Diversification In SLE FlaresNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1998–2001
Rand. Clinical Trial Of High Dose Immunoblative TheraNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1999–2000
Phase IIA Evaluate Effect Of DMP 777 Upon Joint Manifestation In SLENational Center For Research Resources1999
Trial Of B Vitamin Supplementation To Reduce HomocysteineNational Center For Research Resources1997–1999
Hopkins Lupus CohortNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1996
Lupus Cohort Thrombotic Events &Coronary Artery DiseaseNational Heart, Lung, And Blood Institute1994–1995
Lupus Cohort-Thrombotic Events &Coronary Artery DiseaseNational Heart, Lung, And Blood Institute1991–1993